( エーブィエ バイオファーム ) 【日・EUが協定署名】GMP相互承認の対象拡大‐原薬、ワクチンなどカバー 2018年7月23日 (月)厚生労働省は、日本と欧州連合（EU）の間で医薬品のGMP相互承認の対象品目を拡大したことを公表した。17日に日・EU相互承認協定に基づき署名したもの。これまで化学的医薬品の非無菌製剤に限定して、相手国の規制当局によるGMP適合性確認結果を相互に受け入れていたが、新たに原薬（有効成分）、無菌医薬品、ワクチンなど生物学的製剤も対象とし、ほとんどの医薬品をカバーすることとなった。今回の対象品目拡大により、厚労省は「流通製品の一層効率的な品質確保につながることが期待できる」としている。日欧間の貿易に携わる企業の負担軽減を通じて貿易を促進することを目的とした「日・EU相互承認協定」では、GMPの相互承認を定めている。日本・EU加盟各国間で輸出入する場合、相手国の規制当局によるGMP適合性確認結果を受け入れている。さらに、輸入製品を扱う国内製造業者は、輸出元の外国製造業者による試験検査の記録を確認することで、輸入製品の試験検査を実施しなくてもよいとされているが、対象となる医薬品は化学的医薬品の非無菌製剤に限定されていた。
EU and Japan reinforce their collaboration on inspections of medicine manufacturers 18/07/2018 EU and Japan reinforce their collaboration on inspections of medicine manufacturers Update of 2004 mutual recognition agreement extends scope to sterile products, active pharmaceutical ingredients and biologicals including vaccines. The European Union (EU) and Japan have agreed to broaden the range of medicines for which they will recognise each other's inspections of manufacturing sites. The current mutual recognition agreement (MRA) between the EU and Japan has been operational since 29 May 2004. It allows regulators to rely on good manufacturing practice (GMP) inspections in each other's territories, to waive batch testing of medicines that enter Japan from EU countries and vice versa and to share information on inspections and quality defects. Thanks to this agreement, regulatory authorities in the EU and Japan can make better use of their inspections resources by reducing duplication of inspections in each other's territory. The scope of this agreement has now been extended to include sterile medicines, certain biological medicines including vaccines and immunologicals, and active pharmaceutical ingredients (APIs) of any medicine covered in the agreement. This means that authorities from the EU and Japan have agreed that they have equivalent regulatory and procedural frameworks for inspections of manufacturers for these products and can therefore rely on each other's inspections. The full scope of the MRA now covers chemical pharmaceuticals, homeopathic medicinal products (as long as treated as medicinal products and subject to the GMP requirements in Japan), vitamins, minerals and herbal medicines (if considered as medicinal products in both parties); certain biological pharmaceuticals including immunologicals and vaccines, APIs for any of the above categories and sterile products belonging to any of the above categories. In the EU, inspections of manufacturing sites are carried out by national competent authorities from EU Member States. In Japan, GMP inspections are conducted by the Pharmaceuticals and Medical Devices Agency (PMDA)External link icon and the 47 inspectorates of the prefectures. This is the first update of the original MRA agreement. As part of the product scope expansion project, Japan also evaluated and recognised as equivalent all EU competent authorities for human medicines inspection.
Notes The biological pharmaceuticals, including immunologicals and vaccines, in the scope of the agreement are: medicinal products produced by cell culture utilising natural microorganisms or established cell lines; medicinal products produced by cell culture utilising recombinant microorganisms or established cell lines; and medicinal products derived from non-transgenic plants and non-transgenic animals. The update of applicable legislation and recognition of the equivalence of all EU Member States was formalised through an exchange of Diplomatic Notes with Japan published in the Official Journal of the EU External link icon.
No comments:
Post a Comment